360 degree trabeculectomy best way to treat congenital glaucoma

Article

Using a microcatheter to perform 360° trabeculectomy is a safer and more consistent way to treat congenital glaucoma than traditional trabeculectomy, according to information presented at this year's meeting of the American Glaucoma Society (AGS).

Using a microcatheter to perform 360º trabeculectomy is a safer and more consistent way to treat congenital glaucoma than traditional trabeculectomy, according to information presented at this year's meeting of the American Glaucoma Society (AGS).

Adam C. Reynolds, MD of the Dean McGee Eye Institute, University of Oklahoma, US and colleagues performed 360º trabeculectomy using the iTrack catheter (iScience Interventional), a laser guided microcatheter designed to pass 360º through Schlemm's canal, in 12 congenital glaucoma eyes (nine patients) where trabeculectomy or goniotomy would have been the traditional surgical approach. Mean IOP of preoperative eyes was 31 mmHg.

In 75% of treated eyes (n=8), 360º trabeculectomy from a single surgical site was performed successfully. Of the remaining eyes, 50% (n=2) had previously undergone goniotomies, but most of the remaining angle (for a minimum of 200º) was cannulated using this method.

After 6.6 months, two eyes had required shunts to be placed. Although the follow-up period was too short to gauge postoperative visual outcomes, corneal clarity has improved and medical therapy been discontinued in the majority of cases. Mean IOP, postoperatively, was 17 mmHg.

The surgeons concluded that this method of treating congenital glaucoma is effective and offers a lower risk of surgical complications, although the follow-up period was too short to make any definitive assessment of long-term outcomes when compared with traditional methods.

Related Videos
ARVO 2024: Andrew D. Pucker, OD, PhD on measuring meibomian gland morphology with increased accuracy
 Allen Ho, MD, presented a paper on the 12 month results of a mutation agnostic optogenetic programme for patients with severe vision loss from retinitis pigmentosa
Noel Brennan, MScOptom, PhD, a clinical research fellow at Johnson and Johnson
ARVO 2024: President-elect SriniVas Sadda, MD, speaks with David Hutton of Ophthalmology Times
Elias Kahan, MD, a clinical research fellow and incoming PGY1 resident at NYU
Neda Gioia, OD, sat down to discuss a poster from this year's ARVO meeting held in Seattle, Washington
Eric Donnenfeld, MD, a corneal, cataract and refractive surgeon at Ophthalmic Consultants of Connecticut, discusses his ARVO presentation with Ophthalmology Times
John D Sheppard, MD, MSc, FACs, speaks with David Hutton of Ophthalmology Times
Paul Kayne, PhD, on assessing melanocortin receptors in the ocular space
Osamah Saeedi, MD, MS, at ARVO 2024
© 2024 MJH Life Sciences

All rights reserved.